The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study
Wei Jin,1,* Jian-Chun Duan,2,* Zhi-Jie Wang,2 Lin Lin,2 Hua Bai,2 Jie Wang,2 Li Feng1 1Department of Chinese Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People&...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-11-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-effect-and-safety-of-anti-pd-1-singlecombination-therapy-in-refrac-peer-reviewed-article-CMAR |
| _version_ | 1811293275727855616 |
|---|---|
| author | Jin W Duan JC Wang ZJ Lin L Bai H Wang J Feng L |
| author_facet | Jin W Duan JC Wang ZJ Lin L Bai H Wang J Feng L |
| author_sort | Jin W |
| collection | DOAJ |
| description | Wei Jin,1,* Jian-Chun Duan,2,* Zhi-Jie Wang,2 Lin Lin,2 Hua Bai,2 Jie Wang,2 Li Feng1 1Department of Chinese Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Republic of China; 2State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jie WangState Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, People’s Republic of ChinaTel +86 139-1070-4669Email zlhuxi@163.comLi FengDepartment of Chinese Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, People’s Republic of ChinaTel +86 186-1814-7576Email fengli663@126.comAbstract: Immunotherapy provided with checkpoint inhibitors such as the programmed cell death-1 (PD-1) receptor or its ligand-1 (PD-L1) protein has been shown to be effective for treating several types of cancer, and was recently approved for use in treating malignant melanoma, advanced non-small cell lung cancer (NSCLC), urothelial carcinoma, head and neck squamous cell carcinoma, liver cancer, and additional forms of cancer. However, there is little evidence concerning its effectiveness in treating thymic squamous cell carcinoma (TSCC). Here, we report two cases of refractory TSCC that were treated with PD-1 single/combination therapy in a clinical setting. The patients exhibited variable responses to therapy without any serious adverse events. In summary, our findings show that immunotherapy provided with an immuno-checkpoint inhibitor in combination with chemotherapy/anti-angiogenesis therapy can improve the treatment response of patients with refractory TSCC. Anti-PD-1 single/combination therapy may be used as a strategy for treating advanced refractory TC.Keywords: thymic carcinoma, anti-PD-1, single/combination therapy |
| first_indexed | 2024-04-13T04:58:59Z |
| format | Article |
| id | doaj.art-90a4760e7e0646c9983143b848e7c2f6 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-04-13T04:58:59Z |
| publishDate | 2020-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-90a4760e7e0646c9983143b848e7c2f62022-12-22T03:01:23ZengDove Medical PressCancer Management and Research1179-13222020-11-01Volume 12113511135859028The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series StudyJin WDuan JCWang ZJLin LBai HWang JFeng LWei Jin,1,* Jian-Chun Duan,2,* Zhi-Jie Wang,2 Lin Lin,2 Hua Bai,2 Jie Wang,2 Li Feng1 1Department of Chinese Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Republic of China; 2State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jie WangState Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, People’s Republic of ChinaTel +86 139-1070-4669Email zlhuxi@163.comLi FengDepartment of Chinese Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100021, People’s Republic of ChinaTel +86 186-1814-7576Email fengli663@126.comAbstract: Immunotherapy provided with checkpoint inhibitors such as the programmed cell death-1 (PD-1) receptor or its ligand-1 (PD-L1) protein has been shown to be effective for treating several types of cancer, and was recently approved for use in treating malignant melanoma, advanced non-small cell lung cancer (NSCLC), urothelial carcinoma, head and neck squamous cell carcinoma, liver cancer, and additional forms of cancer. However, there is little evidence concerning its effectiveness in treating thymic squamous cell carcinoma (TSCC). Here, we report two cases of refractory TSCC that were treated with PD-1 single/combination therapy in a clinical setting. The patients exhibited variable responses to therapy without any serious adverse events. In summary, our findings show that immunotherapy provided with an immuno-checkpoint inhibitor in combination with chemotherapy/anti-angiogenesis therapy can improve the treatment response of patients with refractory TSCC. Anti-PD-1 single/combination therapy may be used as a strategy for treating advanced refractory TC.Keywords: thymic carcinoma, anti-PD-1, single/combination therapyhttps://www.dovepress.com/the-effect-and-safety-of-anti-pd-1-singlecombination-therapy-in-refrac-peer-reviewed-article-CMARthymic carcinomaanti-pd-1single/combination therapy |
| spellingShingle | Jin W Duan JC Wang ZJ Lin L Bai H Wang J Feng L The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study Cancer Management and Research thymic carcinoma anti-pd-1 single/combination therapy |
| title | The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study |
| title_full | The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study |
| title_fullStr | The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study |
| title_full_unstemmed | The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study |
| title_short | The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study |
| title_sort | effect and safety of anti pd 1 single combination therapy in refractory thymic carcinoma a case series study |
| topic | thymic carcinoma anti-pd-1 single/combination therapy |
| url | https://www.dovepress.com/the-effect-and-safety-of-anti-pd-1-singlecombination-therapy-in-refrac-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT jinw theeffectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy AT duanjc theeffectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy AT wangzj theeffectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy AT linl theeffectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy AT baih theeffectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy AT wangj theeffectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy AT fengl theeffectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy AT jinw effectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy AT duanjc effectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy AT wangzj effectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy AT linl effectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy AT baih effectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy AT wangj effectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy AT fengl effectandsafetyofantipd1singlecombinationtherapyinrefractorythymiccarcinomaacaseseriesstudy |